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LETTERS TO THE EDITOR
Regarding “Percutaneous embolization of a lumbar
pseudoaneurysm in a patient with type IV Ehlers-
Danlos syndrome”
I read with great interest the case report by Naidu et al1
describing a novel percutaneous approach for the treatment of a
pseudoaneurysm in a patient with an Ehlers-Danlos type IV syn-
drome (EDS IV), and I congratulate them for the successful result.
In the discussion of their article, it is stated that an endovas-
cular approach with transarterial coil embolization has been de-
scribed in a patient with EDS IV and hepatic artery aneurysm, and
they cite this paper. I would like to bring to attention that not only
has coil embolization but stent grafting has also been reported for
the treatment of hepatic artery aneurysm in a patient with EDS IV.
In 2004, we reported case of a 26-year-old woman with EDS
IV and hepatic artery aneurysm that was successfully excluded with
a 4-  26-mm balloon-expandable stent graft.2 A self-expandable
stent graft was not considered in that case in order to avoid the
continuous tension on the arterial wall. Balloon expandable stents
bring the maximal radial force to their maximal diameter, 4 mm in
our case. A self-expandable stent would continue to provide con-
tinuous radial force in order to bring the diameter of the stent in its
final size.
In conclusion, stent graft exclusion of small arteries aneurysms
in patients with EDS IV is also feasible. A case of a successful
treatment with a balloon-expandable device has been reported.
Ilias Dalainas, MD, PhD, AFICA
School of Vascular Surgery
University of Milan, Italy
Milan, Italy
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Reply
We greatly appreciate the interest from Dr Casana and col-
leagues regarding our case report describing percutaneous treat-
ment of a pseudoaneurysm in a patient with Ehlers-Danlos type IV
(EDS IV) syndrome.1 We congratulate their results in successfully
treating a hepatic artery aneurysm in an EDS IV patient with a
balloon-expandable stent graft.2
In the case we described, the pseudoaneurysm was not ame-
nable to stent graft placement. It had a wide neck and originated
from a very small lumber artery. An aortic stent graft would not
have been practical, particularly in this patient, with an occluded
aortobifemoral graft.
When the opportunity to use a stent graft arises, the decision
between a self-expanding stent and balloon-expandable stent can
be difficult. Although a self-expanding stent could have a slow
continued radial force on a vessel over a long period of time, a
balloon-expandable stent has the disadvantage of increased wall
tension during its deployment, which may lead to vessel injury in
these patients with very friable tissue. Clearly, appropriate sizing is
mandatory for either stent graft type. In another case report, by
Tonnessen et al, an iliac artery aneurysm in a patient with EDS IV
was successfully repaired using a self-expanding stent graft.3
Each of these challenging patients presented with differing
anatomy and circumstances requiring an individualized approach.
Fortunately, numerous percutaneous and endovascular options are
available.
Sailen Naidu, MD
Mayo Clinic Arizona
Phoenix, Ariz
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Regarding “Screening for abdominal aortic aneurysm
in Canada”
We gratefully appreciate Drs Mastracci and Cinà’s reply1 to our
Letter to the Editor2 regarding their review article.3 Although they
hypothesize in the reply that a reduction in lifestyle-related cardiovas-
cular risk factors, which are addressed when the participants access
medical care for screening, may decrease all-cause mortality in the
screened population, the original studies were not meant or powered
to prove this hypothesis.1 If the hypothesis is valid, nonaneurysm-
related deaths are distributed in attenders for screening less than in
nonattenders for screening or in uninvited controls.
Midterm nonaneurysm-related mortality in attenders for screen-
ing, nonattenders for screening, and uninvited controls was reported
in all the four trials: mean 4.3-year follow-up4 in the Viborg Country
study, median 3.6-years follow-up5 in the Western Australia study,
mean 2.5-year follow-up6 in the Chichester study (men), and mean
4.1-year follow-up7 in the Multicenter Aneurysm Screening Study
(MASS) (Table). Pooled analysis of the four trials (representing
125,576 participants) demonstrated a statistically significant 50%
reduction in midterm nonaneurysm-related mortality with attenders
for screening (9.73%) relative to nonattenders for screening (17.46%)
in a random-effects model (odds ratio, 0.50; 95% confidence interval,
0.48-0.53). Attenders for screening was associated with a statistically
significant 23% reduction in midterm nonaneurysm-related mortality
relative to uninvited controls (12.37%) (odds ratio, 0.77; 95% confi-
dence interval, 0.65-0.90).
Fewer nonaneurysm-related deaths in attenders for screening
may be a result of lifestyle changes (diet, smoking, and exercise)
among participants who were screened (although no specific ad-
vice was given) or treatment of high blood pressure given by the
family physician after measurements taken with the scan.8 Another
explanation could be that people who refuse screening are older
and would be expected to include a high proportion of those
unwell from other causes.6
However, because the merely two trials (median 9.6-year
follow-up9 in the Viborg Country study and over 15-year follow-
up10 in the Chichester study [men]) (representing 18,679 partic-
ipants) reported long-term nonaneurysm-related mortality in at-
1376
tenders for screening, nonattenders for screening, and uninvited
controls, it is unclear in long-term follow-up whether or not the
hypothesis advocated by Drs Mastracci and Cinà1 is valid.
Hisato Takagi, MD, PhD
Norikazu Kawai, MD
Takuya Umemoto, MD, PhD
Department of Cardiovascular Surgery
Shizuoka Medical Center
Shizuoka, Japan
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Table. Midterm outcomes of trials and meta-analyses
Viborg Country
study
Western
Australia study
Chichester study,
men MASS
Publication
BMJ 2005;330:
750
BMJ 2004;329:
1259
Br J Surg 1995;82:
1066-70
Lancet 2002;360:
1531-9 Total
Mean follow-up (y) 4.3 3.6a 2.5 4.1 4.0b
Invited for screening
Attenders
Partticipants (n) 4852 12,203 2342 27,147 46,544
Mortality (n [%])
All-cause 601 (12.39) 1071 (8.78) 326 (13.92) 2590 (9.54) 4588 (9.86)
Aneurysm-related 7 (0.14) 7 (0.06) 4 (0.17) 43 (0.16) 61 (0.13)
Nonaneurysm-related 594 (12.24) 1064 (8.72) 322 (13.75) 2547 (9.38) 4527 (9.73)
Nonattenders
Participants (n) 1481 7149 863 6692 16,185
Mortality (n [%])
All-cause 338 (22.82) 1161 (16.24) 206 (23.87) 1160 (17.33) 2865 (17.70)
Aneurysm-related 2 (0.14) 11 (0.15) 4 (0.46) 22 (0.33) 39 (0.24)
Nonaneurysm-related 336 (22.69) 1150 (16.09) 202 (23.41) 1138 (17.01) 2826 (17.46)
Overall
Partticipants (n) 6333 19,352 3205 33,839 62,729
Mortality (n [%])
All-cause 939 (14.83) 2232 (11.53) 532 (16.60) 3750 (11.08) 7453 (11.88)
Aneurysm-related 9 (0.14) 18 (0.09) 8 (0.25) 65 (0.19) 100 (0.16)
Nonaneurysm-related 930 (14.68) 2214 (11.44) 524 (16.35) 3685 (10.89) 7353 (11.72)
Uninvited controls
Participants (n) 6306 19,352 3228 33,961 62,847
Mortality (n [%])
All-cause 1019 (16.16) 2571 (13.29) 508 (15.74) 3855 (11.35) 7953 (12.65)
Aneurysm-related 27 (0.43) 25 (0.13) 16 (0.50) 113 (0.33) 181 (0.29)
Nonaneurysm-related 992 (15.73) 2546 (13.16) 492 (15.24) 3742 (11.02) 7772 (12.37)
Odds ratio of nonaneurysm-
related mortality
(95% CI)
Attenders vs nonattenders 0.48 (0.41-0.55) 0.50 (0.46-0.54) 0.52 (0.43-0.63) 0.51 (0.47-0.55) 0.50 (0.48-0.53)c
Attenders vs controlls 0.75 (0.67-0.83) 0.63 (0.58-0.68) 0.89 (0.76-1.03) 0.84 (0.79-0.88) 0.77 (0.65-0.90)c
MASS, Multicenter Aneurysm Screening Study.
aMedian.
bWeighted mean excluding the Western Australia study.
cPooled estimate using a random-effects model.
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